GGrantIndex
← Leaderboards

Doris Mangiaracina Benbrook

University Of Oklahoma Hlth Sciences Ctr

Google Scholar ↗PubMed ↗ORCID ↗
$6,963,868
Attributed
$8,161,748
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.8M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,320,523 · 10

By mechanism

P50$9,651,071 · 3
R01$6,213,706 · 4
P30$306,994 · 1
R03$146,500 · 1
M01$2,252 · 1

Top collaborators

Most similar at University Of Oklahoma Hlth Sciences Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsClinical TrialsWomanProteinsCancer TherapyCancer PatientResistanceMalignant Female Reproductive System NeoplasmMolecularApoptosisPreventGenesSheta2In VivoToxic EffectGrowthProgramsCancer Cell LineHistologyResponseFuturePreventionMutationPre-Clinical

Grant awards (37)

Route 66 Endometrial Cancer SPORE$2,581,832
P50 · FY2025 · CA
Project 1: Targeting HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy$518,102
P50 · FY2025 · CA · contact PI
Route 66 Endometrial Cancer SPORE$2,248,055
P50 · FY2024 · CA
Route 66 Endometrial Cancer SPORE$749,771
P50 · FY2024 · CA
Project 1: Targeting HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy$376,436
P50 · FY2024 · CA · contact PI
Admin-Core-001$194,375
P50 · FY2024 · CA
Route 66 Endometrial Cancer SPORE$194,375
P50 · FY2024 · CA
Route 66 Endometrial Cancer SPORE$2,384,742
P50 · FY2023 · CA
Project 1: Targeting HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy$403,383
P50 · FY2023 · CA · contact PI
Gynecologic Cancers Research Program$54,619
P30 · FY2022 · CA · contact PI
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$204,490
R01 · FY2021 · CA · contact PI
Gynecologic Cancers Research Program$54,619
P30 · FY2021 · CA · contact PI
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$326,469
R01 · FY2020 · CA · contact PI
Gynecologic Cancers Research Program$54,619
P30 · FY2020 · CA · contact PI
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$408,607
R01 · FY2019 · CA · contact PI
Ovarian Cancer Chemoprevention$379,695
R01 · FY2019 · CA · contact PI
Gynecologic Cancers Research Program$57,370
P30 · FY2019 · CA · contact PI
Ovarian Cancer Chemoprevention$465,809
R01 · FY2018 · CA · contact PI
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$176,894
R01 · FY2018 · CA · contact PI
Gynecologic Cancers Research Program$54,619
P30 · FY2018 · CA · contact PI
Gynecologic Cancers Research Program$21,409
P30 · FY2018 · CA · contact PI
Gynecologic Cancers Research Program$9,739
P30 · FY2018 · CA · contact PI
Ovarian Cancer Chemoprevention$500,225
R01 · FY2017 · CA · contact PI
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$425,061
R01 · FY2017 · CA · contact PI
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$595,072
R01 · FY2016 · CA · contact PI
Ovarian Cancer Chemoprevention$503,992
R01 · FY2016 · CA · contact PI
Ovarian Cancer Chemoprevention$611,847
R01 · FY2015 · CA · contact PI
Mechanism of SHeA2 Action in Ovarian Cancer$272,533
R01 · FY2009 · CA · contact PI
Mechanism of SHeA2 Action in Ovarian Cancer$272,533
R01 · FY2008 · CA · contact PI
Mechanism of SHeA2 Action in Ovarian Cancer$272,533
R01 · FY2007 · CA · contact PI
Mechanism of SHeA2 Action in Ovarian Cancer$266,924
R01 · FY2006 · CA · contact PI
Mechanism of SHeA2 Action in Ovarian Cancer$244,477
R01 · FY2005 · CA
Steroids and Stem Cell in Carcinogenesis$73,250
R03 · FY2004 · CA
Dawn Hope Tissue Bank$2,252
M01 · FY2004 · RR
Steroids and Stem Cell in Carcinogenesis$73,250
R03 · FY2003 · CA
MECHANISM &POTENTIAL OF RETINOID &DNA DAMAGE THERAPY$143,412
R01 · FY2001 · CA
MECHANISM &POTENTIAL OF RETINOID &DNA DAMAGE THERAPY$143,133
R01 · FY2000 · CA